Management of Mediastinal Lymphadenopathy Detected on Low‑Dose CT

1. Referral and Primary Specialty

Pulmonology should be the first specialty consulted for mediastinal lymphadenopathy because it provides expertise in diagnostic bronchoscopy and coordinates multidisciplinary thoracic care. [4][5]
Even when the lymph nodes show a slight size reduction, referral for tissue diagnosis via minimally invasive endosonographic techniques (EBUS‑TBNA or EUS‑FNA) is recommended to exclude malignancy and guide therapy. [1][2]3

Mediastinal lymphadenopathy identified on low‑dose CT confers a 4.4‑fold higher risk of lung cancer (≈17 % vs ≈4 % in patients without lymphadenopathy). 6

Cases should be reviewed in a multidisciplinary meeting that includes pulmonology, radiology, and thoracic surgery to integrate clinical context (e.g., smoking history, age, comorbidities). [4][5]
Decision‑making should consider lymph‑node characteristics such as size, anatomic location, number of stations, and PET avidity when available. [1][2]
The presence of concurrent pulmonary nodules or masses influences the diagnostic pathway. [1][7]

If a PET‑CT has not been performed, it should be obtained to (a) evaluate metabolic activity of the nodes, (b) detect extrathoracic metastases, and (c) select the most FDG‑avid node for biopsy. [1][9]6
PET positivity alone does not establish a diagnosis because inflammatory conditions (e.g., sarcoidosis, tuberculosis) can produce false‑positive uptake; tissue confirmation remains mandatory. [1][6]

Endosonographic sampling (EBUS‑TBNA or EUS‑FNA) is the recommended initial diagnostic test for discrete mediastinal nodes, offering a high diagnostic yield (≈93 %). [1][2][6][3]8
Specificity of these techniques ranges from 96 % to 100 %. [8][3]
The procedures are minimally invasive, usually performed without general anesthesia, and are less costly than surgical staging. 3

When endosonography is negative but clinical suspicion remains high, mediastinoscopy or video‑assisted mediastinoscopy (VAM) should be pursued, as they provide the highest negative predictive value for ruling out mediastinal disease. [1][2]6

In cases of bulky or matted mediastinal infiltration that cannot be measured discretely, radiographic assessment alone may be acceptable if the disease burden is unmistakable; however, tissue diagnosis is still preferred when feasible to inform treatment planning. [2][6]8

Assuming size reduction equals benign pathology – decreasing node size does not exclude malignancy such as lymphoma or partially treated infection.
Relying solely on imaging – the negative predictive value of TBNA is about 71 %; imaging alone is insufficient to forgo tissue diagnosis. [8][2]
Skipping endosonography and proceeding directly to surgery – this increases patient morbidity and health‑care costs when minimally invasive methods have excellent yield. [1][3]
Inadequate sampling – multiple needle passes and on‑site cytopathology assessment improve diagnostic yield. [8][10]

Thoracic surgery may be indicated when a concurrent lung mass requires resection, when endosonographic techniques are unavailable or have failed, or when an anterior mediastinal (e.g., thymic) mass necessitates surgical excision. [4][5][1][2]11
Interventional radiology (CT‑guided biopsy) is a second‑line option for lymph nodes that are percutaneously accessible (≥ 1.5 cm, favorable trajectory) when endosonography and surgery are not feasible. [8][7]
Oncology referral should occur after tissue diagnosis unless there is overwhelming radiographic evidence of widespread metastatic disease. [2][6]